Pavmed Inc (PAVM) 13F Filing Data & Analysis (Q2 2026)

PAVM ranks #8385 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

20 institutions disclose a position in PAVM, but none treat it as a major bet — even Two Seas Capital LP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

PAVM is down 3% today, but institutions show net buying of $2.5M this quarter — a divergence between today's price move and the underlying institutional flow.

PAVM reported a net loss of $12.1M over the trailing twelve months.

• Not yet profitable — net loss of $12.1M over the trailing twelve months
• Revenue declined 89.0% year over year
• Net income declined year over year, from $72.9M to -$12.1M
• Operating cash flow was negative, using $5.2M in cash
• Current ratio of 0.17x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.49x equity — within a conventional range